Does tesamorelin reduce visceral fat better than other peptides?
Tesamorelin has the strongest clinical evidence — the only peptide FDA-approved for visceral fat reduction. HGH fragment and AOD-9604 lack equivalent human trial data.
Updated May 10, 2026 · 3 min read
For evidence quality, nothing in the peptide world touches tesamorelin for visceral fat. It's the only GH-axis peptide with FDA approval for visceral adiposity — granted for HIV-associated lipodystrophy — and it has multiple randomized controlled trials behind it. The catch: even tesamorelin's trials show the fat comes back within months of stopping. It's not a permanent fix.
What tesamorelin actually is
Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH). Unlike ipamorelin or CJC-1295, which work on the pituitary through different mechanisms, tesamorelin directly mimics the hypothalamic GHRH signal — it's a stabilized version of the 44-amino-acid GHRH molecule with a trans-3-hexenoic acid group attached.
The mechanism for visceral fat loss: GHRH → GH pulse from pituitary → GH's direct lipolytic action, particularly on visceral adipose tissue, which is more GH-sensitive than subcutaneous fat.
The clinical evidence
The pivotal trials (ANRS 099, NOVA, and others) enrolled HIV+ patients with significant visceral fat accumulation. Results at 26 weeks:
- ~15–20% reduction in visceral adipose tissue (VAT) measured by CT scan
- Significant improvements in waist circumference and trunk-to-limb fat ratio
- IGF-1 normalization in GH-deficient participants
The fat loss was statistically robust and clinically meaningful. The problem: at 26 weeks post-cessation, VAT largely returned to baseline. This suggests tesamorelin is managing a GH-deficiency-driven problem, not fixing an underlying metabolic issue.
How it compares to other fat-loss peptides
| Peptide | Evidence for visceral fat | Human RCT data? | FDA approval? |
|---|---|---|---|
| Tesamorelin | Strong (15–20% VAT reduction) | Yes, multiple | Yes (lipodystrophy) |
| HGH fragment 176-191 | Weak; mostly animal models | No robust human trials | No |
| AOD-9604 | Weak; Phase 2 trials failed to show body weight benefit | Phase 2 ran, Phase 3 not pursued | No |
| Ipamorelin + CJC-1295 | Indirect (via GH pulses); body comp improvement reported but VAT-specific data lacking | No | No |
| MK-677 | Some body comp improvement in trials; not VAT-specific | Yes (GH deficiency, frailty contexts) | No |
The comparison matters: HGH fragment 176-191 is widely marketed as a fat-loss peptide, but its human evidence base is essentially zero. AOD-9604 actually made it further in clinical development but failed to show meaningful benefit in Phase 2. Tesamorelin is the outlier that actually worked in trials.
Practical dosing
Tesamorelin's approved dose is 2 mg subcutaneous daily, administered in the abdomen. Most research-chemical community protocols mirror this, though some use lower doses (1 mg) with reported effect.
Timing notes:
- Taken on an empty stomach (food blunts GH pulses)
- Evening dosing aligns with natural GH secretion patterns
- Cycles of 12–26 weeks are common, with breaks to allow natural GH axis recovery
Side effects to know
At 2 mg/day, the main reported effects:
- Edema and joint discomfort in the first 2–4 weeks — typical GH-class effect, usually resolves
- Glucose elevation — GH is counter-regulatory to insulin; monitor fasting glucose
- Injection-site reactions — more than some peptides due to the formulation
- IGF-1 elevation — which is the intended mechanism; very high IGF-1 over long periods has theoretical cancer-related concerns
People with diabetes or pre-diabetes should be cautious: tesamorelin's glucose-raising effect is real and documented in the trials.
Bottom line
If reducing visceral fat is your primary goal and you want evidence behind the peptide you're running, tesamorelin is the strongest choice in the GHRH/GH-axis category. If you're healthy, not GH-deficient, and running it for body recomposition, your actual results may be more modest than the HIV-population trials suggest — and the fat may return when you stop. Set expectations accordingly.